Welcome to endoShunt
Innovating the Future of Trauma Care
An advanced, minimally invasive solution designed to targeted control blood flow for control of internal bleeding.
The Problem
For patients with abdominal hemorrhage, surgeons are forced into a race where time may cost lives. A race against blood loss that they can’t see, access, or control fast enough. These patients aren’t lost due to a lack of surgical skill, they are lost due to a lack of time.
The Market
Every day, people suffer life-threatening abdominal injuries from car crashes, falls, and violence. Trauma is the leading cause of death for people under 45, with millions dying globally each year—many on the operating table—due to uncontrolled abdominal hemorrhage.
The Solution
EndoShunt effectively controls hemorrhage from an injury while maintaining blood flow to the rest of the body, providing trauma surgeons with the time they need to perform definitive repairs.
The Gift of Time for Trauma Surgeons
EndoShunt is Nearing Market Readiness
EndoShunt has been developed through a rigorous, iterative engineering process and has demonstrated effectiveness in controlling hemorrhage across a range of testing environments. These results support its potential for impact in trauma care.
Innovating with Purpose to Elevate Trauma Outcomes
Led by trauma surgeons, engineers, and healthtech leaders, our team merges clinical reality with innovation to solve trauma’s most urgent challenges.
Why EndoShunt
EndoShunt is the solution
We provide trauma surgeons with a way to rapidly gain targeted control of abdominal hemorrhage.
Development
EndoShunt has been developed through a rigorous, iterative engineering process over several design cycles and has consistently demonstrated effectiveness in controlling hemorrhage across a variety of testing environments, reinforcing its strong potential in trauma care.
Market Validation
EndoShunt led our cohort through the NSF I-Corps program to kick off our founding, completing 300+ interviews with surgeons, value analysis committee members, hospital administrators, and other key stakeholders to validate clinical needs and refine our go-to-market strategy.
Intellectual Property
EndoShunt’s patent portfolio includes the non-provisional utility patent US-20220305241-A1, along with provisional applications US17656,390, and US63/166,133. The company holds all rights to these patents, safeguarding its pioneering endovascular shunt technology for critical blood vessel conditions.
Path to Patient Impact
Regulatory & Launch Readiness
EndoShunt is advancing toward FDA 510(k) clearance, with a targeted timeline for submission over the next 18 months. In parallel, we are preparing for a focused clinical introduction in U.S. trauma centers which have expressed early support for participation during this pilot phase. The initial rollout will prioritize real-world evidence generation, workflow integration, and insights into training needs across trauma teams. Learnings from this phase will directly inform our broader market entry strategy.
17+
Years Of Excellence
With EndoShunt, you’re not just choosing a device—you’re choosing a future where more trauma patients live.
Our Values
At EndoShunt, we’ve built a solution that addresses this exact problem. Our device is not just another product—it’s a life-saving innovation that bridges the gap between initial stabilization and definitive surgical repair, giving trauma surgeons the power to act decisively in the most critical moments.
Here’s why EndoShunt is the choice for modern trauma care:
speed
Rapidly deployable in critical trauma scenarios, giving surgeons precious time when every second counts
Precision
Provides targeted bleeding control at the source while preserving vital blood flow to downstream organs and tissues.
Innovation
A first-of-its-kind, length-adjustable endovascular shunt designed specifically to address life-threatening abdominal hemorrhage.
Evidence-Based
Rooted in trauma surgeon insights and refined through clinical feedback, pilot site input, and quality improvement initiatives